Kestrel Therapeutics Receives FDA Clearance for Pan-KRAS Inhibitor KST-6051 Phase 1 Trial
核心洞察
Kestrel Therapeutics (搜索) has received FDA IND clearance for KST-6051 (搜索), a potential best-in-class oral pan-KRAS (搜索) inhibitor targeting both active and inactive KRAS states.
The company plans to initiate the first-in-human Phase 1 FALCON trial by the end of Q1 2026, enrolling patients with advanced KRAS (搜索)-mutant solid tumors.
KST-6051 (搜索) utilizes proprietary Switch-II pocket chemistry and has demonstrated robust preclinical efficacy across multiple KRAS (搜索) mutant tumor models.
Kestrel Therapeutics (搜索) Inc., a clinical-stage biotechnology company focused on next-generation small-molecule inhibitors targeting mutant KRAS (搜索), announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for KST-6051 (搜索), an investigational oral pan-KRAS inhibitor. The regulatory milestone enables the company to advance into human clinical testing for a drug designed to target one of cancer's most challenging oncogenic drivers.
The company expects to initiate its first-in-human Phase 1 dose-escalation clinical trial, designated FALCON, by the end of the first quarter of 2026. The study will evaluate safety, tolerability, and preliminary anti-tumor activity in patients with advanced or metastatic KRAS (搜索)-mutant solid tumors, including pancreatic ductal adenocarcinoma (搜索), colorectal cancer (搜索), non-small cell lung cancer (搜索), and other KRAS-driven malignancies.
Novel Mechanism Targets Both KRAS States
KST-6051 (搜索) represents a potential best-in-class approach to KRAS (搜索) inhibition through its unique mechanism of action. The drug is designed as a potent and selective inhibitor of KRAS with activity against the protein in both its active (GTP-bound) and inactive (GDP-bound) states. This dual-state targeting capability leverages proprietary Switch-II pocket chemistry, distinguishing it from existing KRAS inhibitors that typically target only specific mutant forms or conformational states.
"KST-6051 (搜索) represents our next-generation approach to pan-KRAS (搜索) inhibition, leveraging proprietary and unique Switch-II pocket chemistry to target KRAS in both the ON- and OFF-states," said Dr. Frank G. Haluska, President and Chief Executive Officer of Kestrel Therapeutics (搜索). "We are excited to initiate our first study as we work toward initial clinical readouts anticipated in late 2026."
Preclinical Data Support Clinical Advancement
Preclinical studies have demonstrated robust on-target pathway modulation, anti-proliferative activity, and efficacy at well-tolerated doses across multiple human KRAS (搜索) mutant tumor models. These findings provided the foundation for the FDA's IND clearance and support the drug's advancement into human testing.
The clinical development program will ultimately address multiple KRAS (搜索)-driven malignancies, targeting a significant patient population given that KRAS mutations are estimated to occur in approximately 30% of all malignancies. This represents a substantial unmet medical need, as KRAS has historically been considered "undruggable" due to its challenging protein structure and lack of obvious binding pockets.
Strategic Significance for KRAS-Driven Cancers
"IND approval for KST-6051 (搜索) is a significant milestone for Kestrel and an important step forward for patients with KRAS (搜索)-driven cancers," Haluska noted. The regulatory clearance positions Kestrel to contribute to the evolving landscape of KRAS-targeted therapies, an area that has seen renewed interest following recent breakthrough approvals of KRAS G12C-specific inhibitors.
The Watertown, Massachusetts-based company is backed by leading life-science investors including Pfizer Ventures (搜索) and Santé Ventures (搜索). The company's leadership team brings deep expertise and a track record of success in oncology drug discovery and development, positioning it to navigate the complex clinical development pathway for KRAS (搜索)-targeted therapeutics.